OBJECTIVE:
The American College of Cardiology/American Heart Association (ACA/AHA) recently revised their definitions of hypertension (HTN) with the addition of stage 1 HTN (either systolic (SBP) 130-139 or diastolic (DBP) 80-89 mmHg). Because the implications of this new definition in pregnancy are not known, we aimed to determine the frequency of adverse maternal and neonatal outcomes in stage 1 HTN at the last clinic visit before delivery. STUDY DESIGN: Secondary analysis of a multicenter randomized trial of antioxidants to prevent preeclampsia (PE) in singleton nulliparous low-risk women. BP was measured by trained staff and outcomes were adjudicated. For this analysis, we included women who delivered 36 weeks gestation and abstracted their most recent BP in clinic, within 30 days prior to delivery. The higher of systolic (SBP) and diastolic (DBP) was used for classification into: Group 1, those who were never diagnosed with pregnancy associated hypertension (PAH, defined as either SBP >140 or DBP >90 mmHg on two occasions at least 4 hours apart) and their last clinic BP was <130/80 mmHg; Group 2, women without PAH but last clinic BP was consistent with stage 1 HTN by the new classification; and Group 3, those later diagnosed with PAH or had SBP at least 140 or DBP at least 90 mm Hg at their last clinic visit (stage 2 HTN). The primary outcome was a composite of adverse neonatal outcomes. Univariable and multivariable analyses were performed. RESULTS: 8,778 women were included in the analysis with 1,114 (12.7%) who would have been re-labeled as stage I hypertension by the recent guideline (Group 2). Groups differed on baseline and demographic characteristics (table 1). After adjusting for these differences, women in Group 2 did not have higher primary composite maternal (aOR 0.86, 95% CI 0.69-1.07) or neonatal (aOR 0.94, 95% CI 0.74-1.18) adverse outcomes, or other outcomes compared with Group 1 (Table 2) . As expected, women in Group 3 had higher odds of developing the composite maternal outcome (aOR 1.35, 95% CI 1.17-1.56) and various adverse maternal outcomes and their infants had higher odds of developing the primary (aOR 1.47, 95% CI 1.26-1.72) and various secondary outcomes, compared with those from Group 1 ( Were included all patients with PPROM prior to 35 weeks with homecare inclusion criteria. Women were considered suitable for outpatient care if there were no uterine contractions, no clinical and biological suspicion of infection, clinical stability after 5-7 days of hospitalization and a cervix dilatation under 3cm. The primary outcome measure was to study length of latency period (delay between PPROM and delivery). Second outcomes measures were maternal and perinatal morbidities and mortalities RESULTS: Among the 395 women included after PPROM, 191 were managed as outpatients and 204 in hospital. In the outpatient group the length of latency period was longer than in the hospital group (39.0 (20.0 ;66.0) versus 21.0 (13.0 ;42.0)) days ; p<0,001). Concerning secondary outcomes, we report none case of intra uterine fetal death in the outpatient group against 2 (0.9%) in the hospital group, and respectively 3 (1.6%) placental abruption versus 4 (2.0%), and 3 (1.6%) cords prolapse versus 1 (0.5%). Clinical chorioamnionitis was observed in 30 (15.7%) in outpatient group versus 41 (20.1%) in outpatient group (p ¼ 0.02). Concerning neonatal outcome, there were less transfer in neonatal intensive care, less respiratory distress syndrome in the outpatient group than in the hospital group ( 29,4% versus 47,5% ; p < 0,001), less neonatal sepsis ( 13,9% versus 22,1% ; p < 0,037), less chronic neonatal lung disease ( 20,2% versus 36,3% ; p ¼0,001), less bronchodysplasia ( 2,7% versus 9,8% ; p¼0,004) and less pulmonary arterial hypertension (4,8% versus 10,3% ; p¼0,04). There were also lets neonatal death in the oupatient group ( 2,1% versus 3,9%) but the difference was not statistically significant. CONCLUSION: Home management seems to be a safe alternative to hospitalization in selected patients with PPROM between 24 and 35 weeks. However, a randomized study would be necessary to confirm those results.
457 Does prepregnancy weight or maternal BMI at betamethasone administration impact late preterm respiratory morbidity? expected within one week. The recommended dose of BMZ is 12 mg given intramuscularly twice, each dose 24 hours apart, without regard to maternal body mass index (BMI). Our objective was to determine if maternal prepregnancy weight is a risk factor for neonatal respiratory morbidity and to determine if increasing BMI decreased the efficacy of BMZ. STUDY DESIGN: This was a secondary analysis of the Antenatal Late Preterm Steroids (ALPS) trial, a multicenter, double-blind, randomized controlled trial involving 2,831 women between 34 0/7 weeks and 36 6/7 weeks who were randomized to BMZ or a matching placebo (Gyamfi-Bannerman, N Engl J Med 2016). The primary outcome was the rate of composite neonatal respiratory morbidity within the first 72 hours of life that included continuous positive airway pressure or high flow nasal cannula for 2 hours, oxygen requirement with FiO2 of 30% for 4 hours, any mechanical ventilation or perinatal death. We compared the rate of neonatal respiratory morbidity among prepregnancy BMI classes in both the placebo and treatment groups. We also stratified the treatment effect by maternal BMI at the time of delivery. RESULTS: A total of 2,822 women were identified with maternal weight recorded at delivery. 2,740 women also had self-reported prepregnancy weight available. When stratified by prepregnancy BMI class, there was no significant differences in neonatal respiratory morbidity in the BMZ or in placebo groups (Table 1) . When analyzed by BMI at delivery, there was no significant difference in the rate of neonatal respiratory morbidity (Table 2) , and BMI was not a predictor of treatment response (p ¼ 0.57, 95% CI ¼ 0.99-1.02). CONCLUSION: Prepregnancy maternal BMI is not associated with late preterm neonatal respiratory morbidity. Maternal obesity does not decrease the efficacy of betamethasone for preventing neonatal respiratory morbidity in the late preterm period.
458 Betamethasone exposure in women with a history of preterm birth and short cervix OBJECTIVE: Current guidelines recommend serial cervical length (CL) monitoring up to 24 weeks' gestation in women with a prior preterm birth (PTB) to assess for candidacy for ultrasound-indicated cerclage placement. The utility of CL monitoring beyond 24 weeks is debatable, but one potential role of this practice could be to inform timing of betamethasone (BMZ) administration. This study sought to evaluate the patterns of BMZ exposure in an at-risk population with shortened cervical length.
STUDY DESIGN:
Retrospective cohort study of all women with a prior spontaneous PTB who underwent serial CL measurements and progesterone prophylaxis at a large academic tertiary medical center from 2011-2016. Women were grouped by shortest recorded CL (<25mm or 25mm). The primary outcome was initial BMZ administration <34 weeks' gestation. Secondary outcomes included rates of rescue BMZ administration, optimal BMZ exposure (latency to delivery 7) and exposure with term delivery. A secondary analysis was performed by specific indication for BMZ as either: 1) short cervix (<25mm) alone, or 2) clinical symptoms concerning for preterm labor. Poisson regression with robust error variance was used to calculate incidence rate ratios (IRR) for the primary and secondary outcomes adjusting for black race, earliest prior PTB, and current cerclage. RESULTS: There were 829 women who met inclusion criteria over the study period, with 358 (43.3%) and 471 (56.7%) in the <25mm and 25mm shortest CL groups, respectively. Exposure to both an initial and rescue BMZ course were more common in the short cervix group (Table 1) . Although, women with short cervix were more likely to delivery preterm (45.8% vs. 28.3%; p<.01), there was no difference in exposure with term delivery. Overall rates of optimal BMZ exposure were low, but less likely in the short cervix group (7.4% vs. 15.7%; p¼.03). There were significant differences in latency of exposure to delivery by indication for BMZ; Figure 1 . Lastly, women with BMZ exposure for asymptomatic short CL were less likely to have optimal steroid exposure before delivery (1.2% vs. 19.0%; p<.01) and more likely to deliver at term (54.2% vs. 36.4%; p<.01) when compared to women given BMZ for symptoms. CONCLUSION: Women with prior PTB and short CL are more likely to receive both an initial and rescue course of BMZ, but are less likely to have optimal exposure. This study challenges the practice of administering BMZ to women with an asymptomatic short cervix.
